Loading...
Market
Will Editas' in vivo gene therapy be declared the lead program among CRISPR companies by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Industry reports or announcements from major CRISPR-focused companies
Story
Editas Medicine Shifts Focus to In Vivo Gene Therapy for Sickle Cell, Signs $238 Million Biobucks Pact
Oct 24, 2024, 05:36 AM
Editas Medicine is shifting its focus from its lead ex vivo sickle cell treatment to an in vivo gene therapy approach. The company has signed a $238 million biobucks agreement and is seeking a partner for its advanced ex vivo sickle cell disease program. Editas aims to achieve proof-of-concept data and become the first CRISPR-focused company to declare in vivo sickle cell treatment as its lead program. This strategic pivot, announced on Tuesday, is seen as a significant breakthrough in the field of CRISPR gene editing, although major hurdles remain.
View original story
Similar markets
Yes • 50%
No • 50%
CRISPR Therapeutics • 25%
Intellia Therapeutics • 25%
Beam Therapeutics • 25%
Other • 25%
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Yes • 50%
No • 50%
Wave Life Sciences • 33%
ProQR Therapeutics • 33%
Caribou Biosciences • 33%
Other • 1%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
